Therapeutic targeting of amino acid dependency in cancer cells
DOI:
https://doi.org/10.58445/rars.2046Keywords:
amino acids, cancer metabolism, nutrient dependencies, metabolic therapyAbstract
Cancer cells often undergo changes to their metabolism when they mutate, to meet energetic and biosynthetic demands of their high proliferation rates and environment. Recent and ongoing research suggests that some of these nutrients and substances themselves can encourage oncogenic progression by altering cell signaling and blocking cellular differentiation. Such alterations in metabolism were once viewed as an indirect response to cell proliferation and survival signals, but studies show that the changes are as a direct result of modifications made for the cell to become cancerous.T o satisfy mutant changes, cancer cells often require changes made in their metabolic pathways, requiring certain nutrients to progress and causing these cells to become dependent on these nutrients. Newly developed cancer therapy, still in the experimental stages, suggests eliminating or reducing these nutrients as an effective way to disrupt cancer cell activity and eventually, kill the cells. This paper focuses on the developed methods of targeting nutrients necessary to these new metabolic pathways, as a form of cancer treatment.
References
Fan, K., Liu, Z., Gao, M., Tu, K., Xu, Q., & Zhang, Y . (2022). T argeting Nutrient Dependency
in Cancer Treatment. Frontiers in oncology, 12, 820173.
https://doi.org/10.3389/fonc.2022.820173
Ganapathy-Kanniappan, S., & Geschwind, J. F . (2013). Tumor glycolysis as a target for
cancer therapy: progress and prospects. Molecular cancer, 12, 152.
https://doi.org/10.1186/1476-4598-12-152
Pathria, G., & Ronai, Z. A. (2021). Harnessing the Co-vulnerabilities of Amino
Acid-Restricted Cancers. Cell metabolism, 33(1), 9–20.
https://doi.org/10.1016/j.cmet.2020.12.009
Garcia-Bermudez, J., Williams, R. T ., Guarecuco, R., & Birsoy, K. (2020). T argeting
extracellular nutrient dependencies of cancer cells. Molecular metabolism, 33, 67–82.
https://doi.org/10.1016/j.molmet.2019.11.011
Butler, M., van der Meer, L. T ., & van Leeuwen, F . N. (2021). Amino Acid Depletion
Therapies: Starving Cancer Cells to Death. Trends in endocrinology and metabolism: TEM,
(6), 367–381. https://doi.org/10.1016/j.tem.2021.03.003
Parmentier, J. H., Maggi, M., T arasco, E., Scotti, C., Avramis, V. I., & Mittelman, S. D. (2015).
Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines.
Leukemia research, 39(7), 757–762. https://doi.org/10.1016/j.leukres.2015.04.008
Luengo, A., Gui, D. Y ., & Vander Heiden, M. G. (2017). T argeting Metabolism for Cancer
Therapy. Cell chemical biology, 24(9), 1161–1180.
https://doi.org/10.1016/j.chembiol.2017.08.028
Song, M., Kim, S. H., Im, C. Y ., & Hwang, H. J. (2018). Recent Development of Small
Molecule Glutaminase Inhibitors. Current topics in medicinal chemistry, 18(6), 432–443.
https://doi.org/10.2174/1568026618666180525100830
Wilhelm, S. M., Adnane, L., Newell, P ., Villanueva, A., Llovet, J. M., & Lynch, M. (2008).
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and
PDGF receptor tyrosine kinase signaling. Molecular cancer therapeutics, 7(10), 3129–3140.
https://doi.org/10.1158/1535-7163.MCT-08-0013
Gout, P . W., Buckley, A. R., Simms, C. R., & Bruchovsky, N. (2001). Sulfasalazine, a potent
suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an
old drug. Leukemia, 15(10), 1633–1640. https://doi.org/10.1038/sj.leu.2402238
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E.,
Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., Morrison, B., 3rd, & Stockwell, B. R.
(2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell, 149(5),
–1072. https://doi.org/10.1016/j.cell.2012.03.042
Epner, D. E., Morrow, S., Wilcox, M., & Houghton, J. L. (2002). Nutrient intake and
nutritional indexes in adults with metastatic cancer on a phase I clinical trial of dietary
methionine restriction. Nutrition and cancer, 42(2), 158–166.
https://doi.org/10.1207/S15327914NC422_2
De Santo, C., Cheng, P ., Beggs, A., Egan, S., Bessudo, A., & Mussai, F . (2018). Metabolic
therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant
melanoma. Journal of hematology & oncology, 11(1), 68.
https://doi.org/10.1186/s13045-018-0612-6
Koppula, P ., Zhuang, L., & Gan, B. (2021). Cystine transporter SLC7A11/xCT in cancer:
ferroptosis, nutrient dependency, and cancer therapy. Protein & cell, 12(8), 599–620.
Downloads
Posted
Categories
License
Copyright (c) 2024 Janelle Akpan
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.